NCT04650555View on ClinicalTrials.gov

BIO 300 Oral Powder Safety and Pharmacokinetics

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 8, 2020

Primary Completion Date

July 6, 2021

Study Completion Date

July 6, 2021

Conditions
Acute Radiation Syndrome
Interventions
DRUG

BIO 300 Oral Powder

Amorphous solid dispersion of genistein milled into a powder

Trial Locations (1)

55114

Nucleus Network, Ltd (Formally Prism Research, LLC), Saint Paul

Sponsors
All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

Joint Warfighter Medical Research Program

OTHER

lead

Humanetics Corporation

INDUSTRY

NCT04650555 - BIO 300 Oral Powder Safety and Pharmacokinetics | Biotech Hunter | Biotech Hunter